Brian Birchler serves as Executive Vice President of Corporate and Development Operations at Ionis Pharmaceuticals, Inc., a leading biotechnology company pioneering RNA-targeted therapeutics. In this role, he oversees corporate development, strategic partnerships, business operations, and alliance management, driving the company's growth through key collaborations and operational efficiencies. With more than 25 years of experience in the pharmaceutical and biotech sectors, Birchler joined Ionis in 2015 after holding senior positions at Biogen, where he led business development initiatives, and earlier at Genzyme Corporation, focusing on commercial operations and strategic planning. Birchler's tenure at Ionis has been marked by significant achievements, including the negotiation and execution of high-value partnerships with global pharmaceutical giants such as AstraZeneca, Novartis, and Roche, which have expanded Ionis's pipeline and generated billions in potential milestone payments and royalties. He played a pivotal role in the successful commercialization of Spinraza, Ionis's groundbreaking treatment for spinal muscular atrophy, as well as advancing multiple investigational drugs through clinical development. His strategic foresight has helped Ionis navigate complex regulatory landscapes and scale operations to support a robust portfolio of over 40 programs in neurology, cardiology, and rare diseases. Under Birchler's leadership, Ionis has strengthened its position as an innovation leader, achieving multiple FDA approvals and forging alliances that accelerate the delivery of life-changing therapies to patients worldwide. His expertise in fostering cross-functional teams and optimizing development operations continues to propel Ionis toward sustainable growth and long-term value creation.